The New England journal of medicine, 2020-06, Vol.382 (23), p.2187-2196
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
- Ist Teil von
- The New England journal of medicine, 2020-06, Vol.382 (23), p.2187-2196
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Luteinizing hormone–releasing hormone agonists that are used in androgen-deprivation therapy have a slow onset to suppress testosterone levels, and the level of suppression may be incomplete. This randomized trial assessed relugolix, an oral gonadotropin-releasing hormone antagonist with rapid onset, profound suppression of testosterone levels, and rapid recovery after cessation.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2004325Titel-ID: cdi_proquest_journals_2409243200
- Format
- –
- Schlagworte
- Adenocarcinoma - blood, Adenocarcinoma - drug therapy, Administration, Oral, Aged, Aged, 80 and over, Androgens, Antineoplastic Agents, Hormonal - adverse effects, Antineoplastic Agents, Hormonal - therapeutic use, Cardiovascular diseases, Cardiovascular Diseases - chemically induced, Castration, Clinical medicine, Gonadotropin-releasing hormone, Gonadotropin-Releasing Hormone - agonists, Gonadotropin-Releasing Hormone - antagonists & inhibitors, Gonadotropins, Humans, Injections, Subcutaneous, Laboratories, Leuprolide - adverse effects, Leuprolide - therapeutic use, Luteinizing hormone, Male, Metastasis, Middle Aged, Phenylurea Compounds - adverse effects, Phenylurea Compounds - therapeutic use, Pituitary (anterior), Probability, Prostate cancer, Prostatic Neoplasms - blood, Prostatic Neoplasms - drug therapy, Pyrimidinones - adverse effects, Pyrimidinones - therapeutic use, Risk factors, Statistical analysis, Testosterone, Testosterone - blood